[Note: On May 28, HHS finalized new regulations on the IDR process, as discussed here.]
The No Surprises Act (NSA), enacted in 2020, was designed to protect patients from unexpected medical bills in certain healthcare settings. The law primarily
Rivkin Rounds
Your prescribed dose of health law news
Rivkin Rounds, published by Rivkin Radler, covers a broad spectrum of legal topics relevant to individuals and businesses, with a focus on regulatory compliance, healthcare law, corporate governance, and litigation. The blog addresses issues such as Medicaid fraud enforcement, healthcare privacy and HIPAA compliance, corporate transparency laws, and legal considerations in business transactions including mergers and acquisitions. It also discusses developments in elder law, insurance coverage, labor and employment, intellectual property, and real estate law. The content is aimed at providing updates and practical insights on evolving legal requirements and enforcement trends affecting various industries and practice areas.
Latest from Rivkin Rounds - Page 4
NJ Pharmacy Exec Jailed for Kickback Scheme
By Syma Levine
Adam Brosius, a former pharmacy executive, was recently sentenced to 24 months in prison and ordered to pay $33 million in restitution and $27 million in forfeiture.
Brosius was the director and then the president of Main Avenue Pharmacy, a…
Examining AI in Health Care: A Review of Key Strategic, Legal, and Regulatory Considerations
On Thursday, May 28, in the next installment of Rivkin Radler’s Health Law Executive Briefings, Ashley Algazi and Tim Gonzalez will present “Examining AI in Health Care: A Review of Key Strategic, Legal, and Regulatory Considerations.”
As AI technologies become…
FDA Approves Lilly’s Oral GLP-1 Therapy for Obesity
By Atara Kahn
The U.S. Food and Drug Administration (FDA) recently approved Eli Lilly and Company’s oral GLP-1 receptor agonist, Foundayo (orforglipron), for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition.
The approval…
House Ways & Means Hears Testimony on Home Health Fraud
By Jeff Kaiser
On April 21, in a “Hearing on Protecting Patients and Taxpayers: Cracking down on Medicare Fraud,” the House Ways & Means Committee received testimony on hospice and home health fraud from Sheila Clark, President and Chief Executive Officer of the…
Understanding Medicare Revalidation Requirements
In accordance with 42 C.F.R. § 424.515, all healthcare providers participating in Medicare are required to periodically revalidate their enrollment records with the Centers for Medicare & Medicaid Services (CMS) in order to maintain Medicare billing privileges. This routine process…
CMS Directs States to Audit and Revalidate Medicaid Providers
By Tim Gonzalez
The federal government is escalating its crackdown on Medicaid fraud and every state has been placed on notice.
On April 21, Centers for Medicare & Medicaid Services (CMS) Administrator Mehmet Oz announced that all 50 states will be required to…
Rivkin Radler to Exhibit at the 60th Greater Long Island Dental Meeting
Rivkin Radler’s Dental Practice Counseling Group will be exhibiting at the 60th Annual Session of the Greater Long Island Dental Meeting (GLIDM) on April 26 and April 27 at the Hilton Hotel in Melville, NY. GLIDM is a premier dental…
Navigating the Use of Peptides in Medical Spas
By Emily Manning & Eric Fader
Medical spas continue to expand beyond traditional aesthetic services, and peptides have quickly become one of the more heavily marketed offerings in this space. While these products are often positioned as part of a broader “wellness” model, the legal framework…
FDA Clarifies Policies on Compounded GLP-1s, Warns Companies
By Eric Fader
On April 1, the U.S. Food and Drug Administration (FDA) clarified its policies on compounded drugs, including compounded versions of GLP-1 products. Compounders are permitted to produce copies of approved drugs only while those drugs are listed in FDA’s shortage…